drugset / Trial / NCT02531217
Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability profile of ATYR1940 in the treatment of adult participants with molecularly defined genetic muscular dystrophies.
Timeline
- Start
- 2015-08-13
- Primary completion
- 2016-05-26
- Completion
- 2016-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATYR1940 | Unknown | 3 mg/kg | Intravenous |